What is the recommended streptokinase dosage for adult patients with ST‑segment elevation myocardial infarction (STEMI), other acute myocardial infarction, and acute pulmonary thromboembolism?

Streptokinase Dosing for STEMI and Pulmonary Embolism

For STEMI, administer streptokinase 1.5 million IU intravenously over 60 minutes; for acute massive pulmonary embolism, use 1.5 million IU over 2 hours (or the accelerated regimen of 1.5 million IU over 2 hours). 1

STEMI Dosing

The standard streptokinase dose for ST-elevation myocardial infarction is 1.5 million IU administered intravenously over 60 minutes 1. While the 2017 ESC Guidelines recommend fibrin-specific agents (tenecteplase, alteplase, or reteplase) as preferred thrombolytics 2, streptokinase remains widely used in resource-limited settings where these agents are unavailable or cost-prohibitive.

Alternative Accelerated Regimens

Recent evidence suggests accelerated dosing may be equally effective:

• Accelerated regimen: 1.5 million IU over 30 minutes has shown comparable efficacy with no increase in complications 3
• Some protocols use 1.5 million IU over 20 minutes with similar safety profiles 3
• Half-dose regimens (750,000 IU) have demonstrated comparable reperfusion rates in elderly patients (>70 years) with similar mortality but potentially higher bleeding complications 4, 5

Critical Timing Considerations

• Initiate thrombolysis as soon as possible after STEMI diagnosis, preferably in the pre-hospital setting 2
• Treatment within 6 hours of symptom onset is optimal; efficacy decreases significantly after 6 hours 3, 6
• Patients presenting beyond 12 hours generally should not receive thrombolysis unless ongoing ischemia is present

Mandatory Adjunctive Therapy

When using streptokinase for STEMI, you must administer:

• Aspirin (oral or IV if unable to swallow) 2
• Clopidogrel in addition to aspirin 2
• Anticoagulation with either:
  • Enoxaparin IV followed by subcutaneous (preferred over UFH) 2
  • Weight-adjusted UFH bolus followed by infusion 2

Pulmonary Embolism Dosing

For acute massive pulmonary embolism with hemodynamic instability (cardiogenic shock, persistent hypotension with systolic BP <90 mmHg, or requiring cardiopulmonary resuscitation), the recommended dose is:

Streptokinase 250,000 IU loading dose over 30 minutes, followed by 100,000 IU/hour over 12-24 hours 1

Alternative PE Regimens

• Accelerated regimen: 1.5 million IU over 2 hours has proven effective and safe in high-risk PE patients 1, 6
• The accelerated regimen offers faster thrombolysis with comparable safety to extended infusions 6

PE-Specific Considerations

• Greatest benefit occurs when treatment initiated within 48 hours of symptom onset, though efficacy persists up to 6-14 days 1
• Hemodynamic benefits are most pronounced in the first few days; by one week, differences between thrombolysis and heparin alone diminish 1
• Absolute contraindications may become relative in immediately life-threatening high-risk PE (e.g., recent surgery within 3 weeks) 1

Critical Safety Monitoring

Streptokinase-Specific Adverse Effects

Hypotension occurs in approximately 44% of patients receiving streptokinase, typically appearing 9±5 minutes after infusion starts 3. This is streptokinase-specific and does not indicate treatment failure:

• Continue infusion at the same rate despite hypotension 3
• Hypotension resolves spontaneously within 16±6 minutes without specific therapy 3
• Does not adversely affect reperfusion rates, mortality, or stroke incidence 3

Bleeding Risk

• Major bleeding occurs in approximately 13% of patients 1
• Intracranial/fatal hemorrhage rate: 1.8% 1
• Minor bleeding (puncture sites) is common but manageable 6, 7
• Pulmonary hemorrhage is rare but life-threatening; suspect if sudden respiratory compromise develops post-thrombolysis 8

Allergic Reactions

Allergic reactions occur more frequently with streptokinase than fibrin-specific agents 7, 9. Monitor for:

• Urticaria, bronchospasm, anaphylaxis
• Prior streptokinase exposure (within 5 days to 2 years) is a relative contraindication due to antibody formation

Common Pitfalls to Avoid

1. Do not delay thrombolysis for coagulation studies in patients without recent anticoagulant use; discontinue only if INR >1.7 or elevated aPTT 10

2. Do not use streptokinase if the patient received it within the past 5 days to 2 years (antibody-mediated resistance)

3. Do not stop the infusion for streptokinase-induced hypotension unless accompanied by shock or other complications 3

4. Do not use bacteriostatic water for reconstitution; use only sterile water for injection 10

5. Transfer all STEMI patients to PCI-capable centers immediately after fibrinolysis, regardless of apparent success 2

6. Perform rescue PCI immediately if fibrinolysis fails (<50% ST-segment resolution at 60-90 minutes) 2